Floatz logo

Chimeric Antigen Receptor Modified T Cells Infusion

CD30+ Peripheral T-cell Lymphoma

Shandong Qilu Cell Therapy Engineering Technology Co., LtdCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

35 Active assets in the CD30+ Peripheral T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Alliance for Clinical Trials in Oncology
Phase 4BB
Cyclophosphamide
City of Hope Medical Center
Phase 2BB
DEXAMETHASONE
Zhengzhou University
Phase 4BB
FILGRASTIM
City of Hope Medical Center
Phase 2BB
PREDNISONE TABLETS
City of Hope Medical Center
Phase 2BB

View all 50 →

Same molecule, other indications

Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:

B Cell LymphomaDormant
BB
Indicative ·
71 / 100
View asset →
Non Hodgkin LymphomaDormant
BB
Indicative ·
67 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →